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Potential of mean forceThe Inﬂuenza Matrix 2 (M2) protein is the target of Amantadine and Rimantadine which block its H+ channel
activity. However, the potential of these aminoadamantyls to serve as anti-ﬂu agents is marred by the rapid re-
sistance that the virus develops against them. Herein, using a cell based assay that we developed, we identify two
new aminoadamantyl derivatives that show increased activity against otherwise resistant M2 variants. In order
to understand the distinguishing binding patterns of the different blockers, we computed the potential of mean
force of the drug binding process. The results reveal that the new derivatives are less mobile and bind to a larger
pocket in the channel. Finally, such analyses may prove useful in designing new, more effective M2 blockers as a
means of curbing inﬂuenza. This article is part of a Special Issue entitled: ViralMembrane Proteins— Channels for
Cellular Networking.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The Inﬂuenza A virus is an RNA virus of the Orthomyxoviridae family,
giving rise to widespread seasonal epidemics and, less frequently, to
severe pandemics. While the seasonal epidemics have low mortality
rate, past pandemic events caused heavy losses in human lives.
Among these is the Spanish ﬂu (1918), which killed 2–20% of those
infected, with an infection rate as high as 50%. Later, smaller outbreaks
such as the Asian ﬂu (1957) and Hong Kong ﬂu (1968) claimed the
lives of millions, and in 2009, the H1N1 swine ﬂu became a prominent
illness causing agent in children and adults (ages 5–60) [1].
The Matrix 2 (M2) protein is a critical component of the Inﬂuenza A
virus. Residing in the virus membrane, its 97 amino acid long sequence
encompasses a 19-residue hydrophobic transmembrane domain (TM;
residues 25 through 43) and undergoes tetramerization, forming a
pore. The pore functions as an ion-channel, selectively allowing an
inﬂux of H+s during cell infection and acidiﬁcation of the virus lumen
[2–4]. The M2 channel is a member of a group of viral proteins which
enable membrane permeabilization and are involved in the viral patho-
genicity, referred to as Viroporins. Other small hydrophobic proteins
that are included in the group are HIV-1's Vpu, hepatitis C virus' p7
and HRSV's SH proteins [5,6].brane Proteins— Channels for
al Research, Yigal Allon Kinneret
ights reserved.Over the recent years, several structures of the M2 channel have
been published, using NMR methods as well as X-ray crystallography,
mostly by the groups of Chou, Cross and DeGrado (for example, see
[7–10]). Although each structure is slightly different from one another,
they all exhibit the same basic topology of a tetramer composed of tilted
helices. Smaller details, including the tilt angle itself, vary from structure
to structure, and an attempt to compare three of the structures has been
done in the past [11].
The channel has been the subject of extensive research, aswell as the
target of anti-viral agents. The most prevalent drugs that target the
channel's activity are Amantadine and Rimantadine, sold commercially
as Symmetrel and Flumadine, respectively. However, use of these drugs
had led to the development of resistant strains of the virus, and both
drugs are currently not recommended as treatment options as anti-ﬂu
therapy [12,13].
Among themost prominent resistance-conferringmutations are the
substitutions of Ser31 to Asn (S31N) [14] and Val27 to Ala (V27A), the
former being present in the resistant swine ﬂu strain. Additional muta-
tions in other pore-lining residues, such as Ala30 and (rarely) Gly34
have also been reported as resistance conferring [15,16]. Previous
works suggested that these mutations cause changes in the pore radius
thus either interfering with the binding of the drug or rendering the
binding futile [17].
In order to better understand the mechanism of H+ conductance
and resistance acquirement by the channel, various electrophysiological
methods have been implemented, though some were difﬁcult to carry
out due to the acidic environment required to activate the channel
[18,19]. Other studiesmadeuse of the consequence of the channel activ-
ity in order to indirectly measure it. In a method introduced by us in
















Fig. 2.Known andputative inhibitors of theM2 channel: (a) Amantadine, (b) Rimantadine,
(c) Thiophene derivative, and (d) Pyridine derivative.
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alleviated when an effective blocker of the channel is provided. A very
similar system, differing principally by the choice of chimeric construct,
was introduced by Inouye and co-workers in 2013 [21].
In the current study, we scanned a small library of candidate mole-
cules using our bacterial cell-based assay, with the goal of ﬁnding an in-
hibitor to the resistantM2 S31N strain. Twomolecules exhibiting such a
property were found, and in this study we examine the mechanism of
their inhibition by molecular dynamics (MD) simulations.
2. Results and discussion
2.1. Cell based assay for channel blockage
In pursuance of putative inhibitors of the M2 channel, a system for
high throughput screening of molecules was established in our group
in 2011, based on a bacterial assay [20]. A library of compounds was
applied to channel-expressing Escherichia coli, while their growth was
monitored by measuring O.D.600 over time.
When the channel protein is inserted into the plasma membrane, it
facilitates an inﬂux of H+s through the cellular membrane and conse-
quent growth retardation of the bacteria. Induction efﬁciently inhibits
the growth, resulting in two-fold growth retardation, or lower (see
Fig. 1). Accordingly, screening of potential channel blockers may be
achieved by adding various compounds to the growth media and mon-
itoring growth enhancement, as successful blockers of the channel
should allow better bacterial growth.
2.2. Novel potential channel blockers
Among a limited number of compounds tested, two exhibited signif-
icant rescue of the bacterial growth, hinting that they might act as efﬁ-


































Fig. 1. Growth curves of transformed bacteria expressing the M2 channel from the
Singapore strain (a) or the swine ﬂu (b). The different curves correspond to treatments
of different M2 blockers, as indicated. Growth was normalized in relation to the initial
value.compounds, applied at the same concentration as Rimantadine, either
had no effect on growth (growth curves resemble those of No drug;
data not shown), or had minor effect on the Rimantadine-sensitive
Singapore Inﬂuenza A strain channel. The two new compounds alleviat-
ed growth to a higher extent than Rimantadine, in both the Singapore
strain (Fig. 1a) and in the resistant swine ﬂu's M2 channel (Fig. 1b),
which contains the S31N mutation [22]. This implies that the H+ ﬂux
into the bacterial cell has decreased appreciably due to the presence of
the new compounds.2.3. Assessment of the compounds' EC50 and toxicity on bacteria
Based on the initial results from the chemical screening, we con-
ducted an experiment to assess the effectiveness of the newly found
compounds. Using the same expression system mentioned above, we
added each compound in two-fold serial dilutions, varying from
0.8 μM to 50 μM ﬁnal concentrations, to the growth media of the resis-
tant swine ﬂu M2 expressing bacteria. Additionally, we tested the com-
pounds' toxicity upon the bacteria, by applying the same concentrations
on un-induced bacteria. The compounds did not diminish the bacterial
growth rate, as well as the ﬁnal bacterial density (data not shown).
Taken together we can conclude that the new compounds exhibited
no toxicity towards the bacteria.
While Rimantadine could not rescue the growth of bacteria express-
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Fig. 3.Maximal growth rate of bacteria treatedwith the Pyridine derivative, the Thiophene
derivative or Rimantadine. The smooth lines depict the ﬁtted function for dose–response
relationship of the Pyridine derivative or the Thiophene derivative.
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the untreated bacteria (Fig. 3). Note that the growth rates in the pres-
ence of the new compounds did not reach the un-induced bacteria's
maximal growth rate, suggesting that the growth inhibition was not
fully alleviated even in concentrations as high as 50 μM. To quantitate
the effect the compounds have had on the bacterial population, a
dose–response curve was ﬁtted to the data, yielding EC50 = 25.4 ±
1.3 μM for the Thiophene derivative and EC50 = 29.5 ± 2.7 μM for
the Pyridine derivative.2.4. Computational analysis of drug binding
In order to better understand the mode of inhibition, we performed
atomistic molecular dynamics simulations of Rimantadine and its
Pyridine and Thiophene derivatives binding to the M2 channels. Simu-
lations were performed on the TM-domain of a Rimantadine-sensitive
strain (referred to as RS throughout themanuscript) and of the resistant
S31N mutant-strain. At ﬁrst, both channels were simulated for 100 ns
without any drug and maintained a tetramer structure that did not
deviate appreciably from the starting conﬁguration (backbone RMSD
ca. 3 Å and no signiﬁcant deviation in the radius of gyration; see Fig. 4).
Following the simulation of the free channels, we looked into the be-
havior of the channels and of the drug, using either Rimantadine, Pyri-
dine derivative or Thiophene derivative bound to the RS or resistant
M2 channels. We performed umbrella sampling, i.e. we ran many
short simulations of the drug bound all along the pore axis, from the
extracellular water bulk (N-terminus side, designated ‘up’) to the intra-
cellular water bulk (C-terminus side, designated ‘down’). In these simu-
lations, we could see the behavior of the protein and of the drug given
a particular vertically ﬁxed binding location (as well as the resulting
energy proﬁles, as expanded below).
Throughout the simulations, the drugs ﬂuctuated slightly within the
pore, mostlymaintaining an overall linear topology and a parallel orien-
tation with their longest axis stretched and aligned with the pore axis.


























Fig. 4.M2 stability. The backbone RMSD (a) and radius of gyration (b) of the M2 channel
throughout the 100 ns simulations of the RS (black) and S31N resistant mutant (red).when the drug was adjacent to the lower residues, namely His37 and
Trp41, the steric restraints forced the helices to tilt, causing the channel
to switch from a cylindrical shape to a conical-‘teepee-like’ shape. This
behavior is expected as these residues are very bulky and do not allow
much space for anything else within the pore. Nonetheless, this occur-
rencemight not be so frequent in effect since, as the energies below sug-
gest, the drug should bind higher up in the pore (in the N-terminal
direction).2.4.1. Orientation of the drugs in the channel pore
In order to quantitate the above observation, we analyzed the direc-
tion to which the amine group of Rimantadine was pointing, as a
function of the position of the drug within the pore. Two main modes
for Rimantadine were observed: upward facing, with the amine pointing
towards the N terminus (extracellular bulk); and downward facing.
Rimantadine is small enough to rotate freely within the pore, and
therefore spontaneous interconversion between the two modes was
expected. However, the drug was rarely found to be in any ‘in-between’
orientation (the amine group pointing orthogonally to the pore axis).
In Fig. 5 the density of sampling Rimantadine in its full upward
facing orientation is higher, as long as the drug binds the channel
above residue His37. This bias is lost once the drug leaves the pore
and enters the extracellular bulk (right end of the graph). When
Rimantadine is located below His37 the bias changes to the downward
facing orientation, albeit to a lesser extent. Again, Rimantadine has no
ﬁxed orientation as it exits to the intracellular bulk (left end of the
graph). This behavior may be explained by the fact that Rimantadine
is positively charged at physiological pH, and the histidines of M2
have been suggested to be partially charged, with two or three out of
the four histidines being positively charged [7,9]. This causes electro-
static repulsion between the histidines and the Rimantadine amine
group, forcing it to maintain an orientation that maximizes the distance
between the two positively charged groups. This is in line with previ-
ously published work by Leonov et al. [17].
We subsequently repeated the same orientational analysis for the
Pyridine and for the Thiophene derivatives. However, due to the size of
the two derivatives, ﬂipping was not observed in the channel lumen.
Therefore, we performed the simulations on these two derivatives inN
N
N
0 Δ z+Δ z-
H37 H37 H37
Fig. 5. Rimantadine's amine group direction as a function of the position of Rimantadine
along the pore axis of M2 TM domain. The abscissa shows the orientation of the
Rimantadinewithin the pore, ‘up’ being the amine facing theN-terminus of theM2protein
(the extracellular side). The ordinate presents the location of the Rimantadine along the
M2 pore in respect to residue His37: below on the left and above on the right.
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twopossibilities of attachment. Considering that both the Pyridine deriv-
ative and the Thiophene derivative bear no full charge, therewas no rea-
son to assume a priori that one orientation would be favorable.
Note that from a chemical point of view, almost the entire molecule,
for both compounds, is a conjugated system of delocalized electrons. On
top of that, the only rotatable bonds don't produce a substantial change,
upon rotation, in the length of the long axis of the molecule, i.e. the
length and width of the cylinder that makes up the molecule are, in
large, constant. It is therefore not surprising that the compounds bind
the narrow M2 channel with ease, as they hardly lose entropy upon
binding.2.4.2. Potential of mean force analysis
The umbrella sampling set of shorter simulations described above
was collected and unbiased using the WHAMmethod [23], to compute
the free energy proﬁle of the drugs within the channel (a.k.a. potential
of mean force or PMF). The PMF proﬁles were calculated for
Rimantadine, Pyridine derivative and Thiophene derivative, in both
RS, and resistant strains, as seen in Fig. 6. The proﬁle for Rimantadine
in the RS channel exhibits a typical binding curve with a binding site
adjacent to residues 27 and 31, a binding site previously reported both
structurally [24,25] and computationally [17]. However, when residue
Ser31 is mutated to Asn, a well knownmutation that confers resistance
to known drugs [14], the binding trough is diminished and the energies
for binding the channel increase overall. This suggests that the drug
does not bind well and is in line with a model previously suggested
[17] and supported by experimental results [26]. Note that the free
energy increases rapidly as the drug tries to cross His37, probably to
accommodate for the electric repulsion.
Examinationof thenewly found compounds presents a different pic-
ture. Focusing on the upward facing PMFs,mimicking the binding orien-
tation of Rimantadine throughout most of the coordinate, a binding site
appears roughly at the same location as for Rimantadine, near residues
27 and 31, as well as an energy barrier near His37. In the RS strain, a
second binding site near Leu40, which is at the edge of the pore, can
be seen. The compounds, which are much larger than Rimantadine,
allow more interactions through the non-adamantyl portion, probably
allowing the formation of the second binding site.
Moving on to the S31N resistant mutant, the curves present an ener-
gy proﬁle where the second binding site is replaced by an energy barrier.
Interestingly, the ﬁrst ‘Rimantadine-like’ binding site is present and is
mostly unchanged. This could explain why these compounds are still




























Fig. 6. The potential of mean force of the various drugs along theM2 pore axis. The free energy p
compounds, full lines represent the upward facing orientation and the dashed lines represent t
chain of the indicated residue; top triangles belong to the resistant mutant, bottom triangles be
(b) Pyridine derivative; (c) Thiophene derivative.Looking at the PMFs of the downward facing orientation, the differ-
ences in energies are surprisingly not as dramatically different as one
might expect. For the case of the Pyridine derivative compound binding
the RS strain, the binding energies seem to be highly similar to the up-
ward facing orientation energies, but the energy barrier seems to be
much lower, suggesting that the downward facing binding is energeti-
cally favorable. Binding to the S31N mutant introduces a new energy
barrier near Val27. In this case, we expect that the binding of the com-
pound in downward facing orientation will be less common, but more
long lasting, since the energy trough is situated between two high
peaks. This would imply a lower kon and koff, with no clear conclusion
on the difference in Kd.
In the case of the Thiophene derivative compound, we cannot detect
a principal difference for the S31N mutant; however, the curve for the
downward facing binding to the RS strain is intriguing: the energy pro-
ﬁle presents energy barriers that are smaller than previously discussed
energy barriers (by at least 5 kBT) on both sides of a novel binding site
situated near Gly34. Kinetically, even though this binding trough is as
deep as the binding troughs of the upward facing curve, it is expected
to be seldom visited because the funnel entry is narrow. In other
words, the energetically preferred route to the binding site demands
the compound's upward position, arguing statistical unlikelihood of
the downward position's binding.
While the energy proﬁles may explain binding of the compounds to
M2, the question of how they actually inhibit the channel remains open.
Rimantadinewas previously suggested to inhibit theprotonﬂuxby sim-
ple charge repulsion [17], and indeed we were able to reproduce these
results (data not shown). However, we do not see the same focused
positive electrostatic potential for the uncharged Pyridine derivative
and Thiophene derivative. This raises an interesting conclusion that
M2 may be inhibited in more than one way. The inhibition could be
explained by steric hindrance, being more bulky than the smaller
Rimantadine, or by limiting protein ﬂexibility and attached water,
whichmight interferewith H+ conductance. However, further clariﬁca-
tion on the modes of inhibition will require more research.
To conclude, the PMF proﬁles suggest that, in contrast to Rimantadine,
which does not bind the S31N mutant appreciably, the compounds we
present maintain some form of binding. This might be due to the exis-
tence of twomodes of binding (ormore, if considering the downward fac-
ing modes of binding) which are not fully abolished by the resistance
conferring mutation (a representative snapshot of one such mode of
binding is shown in Fig. 7). This should explain why the Pyridine deriva-
tive and the Thiophene derivative show some sort of inhibition on the re-
sistantmutant S31N. This presents an encouraging turning point towards






















roﬁle of the RS channel is in black, while that of the S31N resistantmutant is in red. For the
he downward facing orientation. The triangles present the average coordinate of the side-





Fig. 7. A representative snapshot of the compounds bound in an upward facing conforma-
tion, in the S31N M2 channel. The front helix of the M2 bundle was removed for better
visualization. The Pyridine derivative is shown in panel a and Thiophene derivative in
panel b.
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3.1. Chemicals
1-Aminoadamantane (Amantadine) and racemic 1-(1-adamantyl)-
ethanamine (Rimantadine) were purchased from Sigma-Aldrich labora-
tories. N-(((1-(1-adamantyl)ethyl)amino)carbonothioyl)-3-(2-thienyl)
acrylamide (Thiophene derivative, compound 5197035) and N-(((1-
(1-adamantyl)ethyl)amino)carbonothioyl)-nicotinamide (Pyridine de-
rivative, compound 5150923) were purchased from ChemBridge Corpo-
ration (San Diego, CA) andwere dissolved in DMSO to a concentration of
5 mM; for chemical structures of the compounds, see Fig. 2. Isopropyl-β-
D-thio-galactopyranoside (IPTG) was purchased from Biochemika-Fluka
(Buchs, Switzerland). The pMal-p2x vector was purchased from New
England Biolabs (Ipswich, MA). DH10B E. coli cells were purchased
from Invitrogen (Carlsbad, CA).3.2. Plasmids and bacterial strains design
The Singapore M2 sequence was synthesized via a multistep PCR
protocol. This RS construct was designed according to the Singapore
H2N2 isolate, M2 sequence [15], and was inserted into pMal-p2x
using the methods stated in [20] so it was in frame to the carboxy-
terminus of the MalE protein, following a poly-Asn site. The plasmid
was inserted into E. coli of the DH10B strain. The swine ﬂu strain [27]
was obtained through point mutations on the Singapore strain with
the Quick multi-Mutagenesis kit from Stratagene (La Jolla, CA).3.3. Bacterial growth
Cells bearing or lacking (as a control) the ion channel genes were in-
cubated overnight in LB with 100 μg/ml Ampicillin. Thereafter, the
growth culture was diluted 100 fold and the bacteria were grown
until their O.D.600 reached 0.07–0.1. Cells were then divided into 96
well ﬂat-bottomed plates (from Nunc, Roskilde, Denmark) containing
the different treatments. The growth volume in each well was 100 μl.
In the chemical screening assay, IPTG to a ﬁnal concentration of 60 μM
was added to the cells; in the dose–response assays, IPTG concentration
was 35 μM inHigh induction experiments, or≤17.5 μM in Low induction
experiments. D-glucose was added, to a concentration of (1%). The ﬁnal
concentration of DMSO was 1%. 96 well plates were incubated for 16 h
at 30 °C in a Synergy 2 multi-detection micro-plate reader from BioTek
(Winooski, VT), or in Inﬁnite 200 from Tecan Group (Männedorf,
Switzerland) at a constant high shaking rate. O.D.600 readings were
recorded every 15 min. For every measurement, duplicates or more
were done.3.4. Dose–response relationship
Effective-concentration of 50% (EC50)was derived bymeasuring the
dose–response effect of the Pyridine derivative or the Thiophene deriv-
ative upon themaximal growth rate of the channel-expressing bacteria.
To the resulting data we non-linearly ﬁt a curve according to the equa-
tion relating the maximal growth rate (R) to the drug concentration:
y ¼ R0 þ
Rmax−R0
1þ REC50ð Þn
where R0 is themaximal growth ratewithout a drug, Rmax is themaximal
growth rate when all growth-inhibition is lifted, and n is the maximal
slope of the curve.
3.5. Molecular dynamics
For the simulation system of the RS M2, we used the recent X-ray
structure of the M2's TM domain tetramer, taken from the PDB (PDB
ID: 3LBW, [7]). We reverted residue 34 to wt Gly; the N-termini were
capped with acetyl groups, and crystallographic water molecules were
kept in the system.
For the simulation system of the resistant M2, we used the structure
of the S31N mutant solved by NMR (PDB ID: 2LY0, [10]). We clustered
the 20 structures together using g_cluster from the GROMACS package
[28,29], using a cutoff that would include all 20 structures in the same
cluster, and the frame that was the closest (by RMSD) to the represen-
tative structure was chosen. The drug molecule was removed from the
structure, and the N-termini were capped with acetyl groups. In both
systems, the protonation pattern for His37 was that of two opposing
positively charged histidines.
Next, each of the two systems underwent the following procedure:
The system was embedded in a pre-equilibrated DMPC membrane so
that the protein is perpendicular to the membrane plane, and all
clashing lipids and water molecules within 2 Å of the protein were de-
leted. The system's chargewas neutralized by addingK+ andCl− ions to
a ﬁnal concentration of 140 mM, randomly distributed. The systemwas
then subjected to energy minimization using the steepest descent algo-
rithm, with a tolerance of 1000 kJ·mol−1·nm−1, followed by twomore
steps using the conjugated gradient algorithm, with tolerances of 100
and 10 kJ·mol−1·nm−1. After the minimization step, the system was
equilibrated by simulating it under positional restraints on the protein
(and crystallographic water molecules, if present), with a harmonic
force constant of k = 1000 kJ·mol−1·nm−2 for 1 ns. This step was re-
peated using a force constant of k = 500 kJ·mol−1·nm−2 for 100 ps,
and a ﬁnal step of unrestrained simulation of another 1 ns. The gradual
removal of the restraints allowed for the lipids and water molecules to
pack more tightly around the protein, preventing the tetramer from
breaking apart.
For the structure and topology of the drugs, we used the ATB server
[30] to construct initial models of the molecules with partial charges
and bonded parameters. The parameters were slightly modiﬁed based
on chemical considerations as suggested by Professor Silvio E. Biali
from the Hebrew University of Jerusalem, Israel (personal communica-
tion); bond lengths were ﬁtted to similar known molecules already
existing in the GROMACS database (e.g. the pyridine group was based
on NADH) and several angle rotations were limited to account for reso-
nance and conjugation effects (also in line with reported number of ro-
tatable bonds from ChemBridge). The molecules were then submitted
to MD simulations in water for equilibration and parameter validation.
3.6. MD details
The simulations were conducted using the GROMACS package
[28,29], employing an extended version of the GROMOS53a6 force ﬁeld
[31]. All simulations were conducted using the LINCS algorithm [32] to
1073R. Alhadeff et al. / Biochimica et Biophysica Acta 1838 (2014) 1068–1073constrain bond lengths and angles of hydrogen atoms, allowing a time
step of 2 fs. Simulationswere run using Berendsen temperature coupling
at 310 K employing a coupling constant of τ = 0.1 ps. Pressurewas kept
constant at 1 bar by applying semi-isotropic coupling with a coupling
constant of τ = 1 ps, differentiating the z axis (the membrane normal).
A cutoff of 1.2 nm was used for van der Waals interactions, and long
range electrostatic interactions were computed using the PME method
[33]. The water model used was SPC [34].
3.7. Potential of mean force (PMF)
We applied umbrella sampling [35] in order to compute the PMF of
the various drugs in the pore of the M2 channel. The simulations were
composed of the equilibrated M2 channel (RS strain or drug resistant)
and an equilibrated drug (Rimantadine, Pyridine derivative or Thio-
phene derivative). The drug was aligned to the M2 axis and inserted
into the pore in such a way that it will not clash with any residue,
while clashing water molecules were moved if needed. The various
frames were constructed by placing the drug along the z-axis at 2 Å
intervals, simulating the system for each position. Additional frames
were added to compensate for poor sampling, until the histograms
were sufﬁciently overlapped, making up between 30 and 40 frames
for each combination of drug-strain. Each frame was energy minimized
using the same parameters as above and then subjected to a 10 ns sim-
ulation. The harmonic force was applied to the z-axis only, using a con-
stant of k = 1000 kJ·mol−1·nm−2. Unbiasing and integration were
done using the Weighted Histogram Analysis Method (WHAM) [23].
3.8. Visualization and analysis
The simulations were visualized with the visual molecular dynamics
(VMD) program [36]. The analyses were conducted using in-house VMD
Tcl scripts, in-house purpose written perl scripts, and the GROMACS
analysis package tools. For the image of the bound drug in the M2 chan-
nel a frame from the umbrella sampling data set was selected, where the
z-coordinate of the drug ﬁts the energy trough.
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